Navigation Links
Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
Date:6/2/2009

ss and concern of CDI among medical professionals and public health officials.

Scheduled Conference Call

The Company will host a conference call for the investment community today beginning at 3:00 p.m. Pacific time (6:00 p.m. Eastern time) to discuss the additional fidaxomicin Phase 3 data and answer questions.

To participate in the live call by telephone, please dial (877) 419-6590 from the U.S., or (719) 325-4893 from outside the U.S. The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com.

About Fidaxomicin

Fidaxomicin is the first in a new class of antibiotics called macrocyclics, which inhibit the bacterial enzyme RNA polymerase, resulting in the death of Clostridium difficile. The narrow spectrum profile of fidaxomicin may eradicate Clostridium difficile selectively with minimal disruption to the normal intestinal flora. This may facilitate the return of the normal physiological conditions in the colon and reduce the probability of CDI recurrence.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infective products to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin, formerly known as OPT-80, is the only antibiotic therapy currently in Phase 3 worldwide clinical development for Clostridium difficile infection. Prulifloxacin is an antibiotic which has completed two Phase 3 clinical trials for the treatment of travelers' diarrhea, a form of infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... University Bloomington have described the self-assembly of large, ... potential value for the field of organic electronic ... , Their paper, "Anion-Induced Dimerization of 5-fold Symmetric ... Crystals," has been published online by Chemical ... of Chemistry. It is the first collaboration by ...
(Date:7/31/2014)... Yonkers, NY (PRWEB) July 31, 2014 ... use in high temperature oven carts. These bearings are ... occur in sealed ball bearings because of the ... purity alumina requested help from the design engineers at ... through a heating process. During their manufacturing operation, pans ...
(Date:7/31/2014)... July 31, 2014 CollabRx, Inc. (NASDAQ: ... therapeutic decision-making in oncology, today announced that it will ... to discuss the Company's financial results for the first ... about the business in the current fiscal year. , ... on Thursday, August 14, 2014, at 5 p.m. EDT ...
(Date:7/31/2014)... 31, 2014 Held at the Stanford ... an overview of the disease and its treatment. Survivors ... effects, as well as updates on the state-of-the-art with ... Sandy Srinivas for organizing this educational opportunity,” says KCA ... “Sandy and her colleagues have put together a program ...
Breaking Biology Technology:Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3CollabRx, Inc. Schedules First Quarter Fiscal Year 2015 Financial Conference Call and Business Update 2
... YORK, Sept. 13 Regenicin™, Inc. ... clinical-stage biotechnology company, announced today that John J. Weber, ... Medical Systems, USA, Inc. ("Fujifilm USA"), has agreed to ... of directors and interim Chief Financial Officer.  Weber brings ...
... CLEVELAND, Sept. 13 /PRNewswire/-- DATATRAK International, Inc. (OTCQX: DATA), a ... for the clinical trials industry, announced today that Zacks ... effective September 13, 2010. Zacks is a leading provider ... this research report can be obtained by contacting Mr. ...
... Inc. (OTC Bulletin Board: CSBR ), a company ... specific data to enhance the value of oncology drugs, today ... ended July 31, 2010.  Full details of the Company,s financial ... www.championsbiotechnology.com . Total revenues for the first ...
Cached Biology Technology:Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO 2DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research 2DATATRAK International, Inc. Announces Initial Equity Research Coverage by Zacks Investment Research 3Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results 4
(Date:7/31/2014)... the United States, natural-gas production from shale rock ... 2007. Yet scientists still do not fully understand ... to a report in the journal Frontiers ... gas extraction continues to vastly outpace scientific examination, ... organizations and institutions, including Princeton University, concluded that ...
(Date:7/31/2014)... By tracing nearly 3,000 genes to the earliest ... Florida scientists have created an extensive "Tree of ... next-generation DNA sequencing. , Among the study,s ... to small moths than to large ones, which ... The study also found that some insects once ...
(Date:7/31/2014)... study (HPV-023; NCT00518336) shows the sustained efficacy, ... virus (HPV) vaccine Cervarix. Women vaccinated with ... more than nine years, and vaccine efficacy ... is the longest follow-up report for a ... for the full paper. , HPV ...
Breaking Biology News(10 mins):'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... Head and neck cancer is the sixth most common ... demographic groups, including young women without any known risk factors. ... may increase the movement of precancerous cells in the mouth ... oral cavity. The new results, published in the ...
... adult height may be caused by genetic inheritance, but a ... to be discovered. Now a new meta-analysis of ... over two dozen genes that were not previously associated with ... 30 previously known height genes. "Although the discoveries may not ...
... The hair color of an unknown perpetrator who has ... for forensic investigators. Erasmus MC scientists, in collaboration with their ... predict people,s probable hair color. Their findings will be published ... The research findings demonstrate that on the basis of DNA ...
Cached Biology News:Estrogen may help precancerous cells spread in oral cavity 2CHOP-led study detects dozens of genes for adult height 2CHOP-led study detects dozens of genes for adult height 3Hair color of unknown offenders is no longer a secret 2
... is the research-grade spectrofluorometer with a minimum ... S/N ratio 200 or greater for the ... especially designed to keep in mind in ... kinetics, stopped-flow, titration, or anisotropic measurements. ,The ...
... Microarrays designed for genome-wide microRNA expression ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive microRNA Expression ... The Fishes microRNA Microarray contains ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known virus microRNAs ...
... The LTQ XL extends the legendary MSn ... to generate structural information through Thermo Scientifics ... Scientific's LTQ XL is the only mass ... ETD and CID. Pulsed Q Collision ...
Biology Products: